The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Inogen shares have lost about 22.9% since the beginning of the year versus the S&P 500's decline of -4.7%. What's Next for Inogen? Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago. These fig ...

This quarterly report represents an earnings surprise of 3.33%. A quarter ago, it was expected that this server technology company would post earnings of $0.60 per share when it actually produced earnings of $0.61, delivering a surprise of 1.67%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Super Micro, which belongs to the Zacks Computer- Storage Devices industry, posted revenues of $4.6 billion for the quarter ended March 2025, surpassing the Zacks Consensus Es ...

Group 1 - Arcutis Biotherapeutics reported a quarterly loss of $0.20 per share, which was better than the Zacks Consensus Estimate of a loss of $0.21, and an improvement from a loss of $0.32 per share a year ago, resulting in an earnings surprise of 4.76% [1] - The company achieved revenues of $65.85 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26%, and showing a year-over-year increase from $49.57 million [2] - Over the last four quarters, Arcutis Biotherapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2 - The stock has increased approximately 10.6% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $72.93 million, and for the current fiscal year, it is -$0.55 on revenues of $307.74 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis Biotherapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.15, delivering a surprise of 66.67%.Over the last four quarters, the company has sur ...

UL Solutions Inc. (ULS) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.63%. A quarter ago, it was expected that this company would post earnings of $0.38 per share when it actually produced earnings of $0.49, delivering a surprise of 28.95%.Over the last four quarters, the company ...

Core Viewpoint - Crescent Energy (CRGY) reported quarterly earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.47 per share, and showing an increase from $0.46 per share a year ago, representing an earnings surprise of 19.15% [1][2] Financial Performance - The company posted revenues of $950.17 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.40%, and up from $657.47 million year-over-year [2] - Over the last four quarters, Crescent Energy has exceeded consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Crescent Energy shares have declined approximately 41% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates at $0.26 for the upcoming quarter and $1.66 for the current fiscal year, with revenues expected to be $898.17 million and $3.7 billion respectively [7] Industry Context - The Alternative Energy - Other industry, to which Crescent Energy belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Crescent Energy's stock performance [5]

Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.16 per share when it actually produced a loss of $0.11, delivering a surprise of 31.25%.Over the last four quarters, the company has sur ...

Core Viewpoint - Standex International (SXI) reported quarterly earnings of $1.95 per share, exceeding the Zacks Consensus Estimate of $1.93 per share, and showing an increase from $1.75 per share a year ago, indicating a positive earnings surprise of 1.04% [1] Financial Performance - The company achieved revenues of $207.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.33%, compared to $177.27 million in the same quarter last year [2] - Over the last four quarters, Standex has consistently surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Stock Performance and Outlook - Standex shares have declined approximately 24.4% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $2.33 on revenues of $220.56 million, and for the current fiscal year, it is $7.86 on revenues of $785.88 million [7] - The estimate revisions trend for Standex is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Manufacturing - General Industrial industry, to which Standex belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -76.19%. A quarter ago, it was expected that this cancer drug developer would post a loss of $0.70 per share when it actually produced a loss of $0.79, delivering a surprise of -12.86%.Over the last four quarters, the ...

Core Viewpoint - Atmos Energy Corporation (ATO) is expected to report its second-quarter fiscal 2025 results on May 7, with an earnings surprise of 1.4% in the previous quarter [1] Group 1: Factors Impacting Q2 Earnings - Strategic investments and modernization of transmission and distribution systems are likely to have positively impacted the company's bottom line [2] - An expanding customer base and implementation of new rates in service regions are expected to contribute positively to earnings [3] - Higher distribution revenues and lower interest expenses are anticipated to further benefit the quarterly performance [3] - However, increased operation and maintenance expenses, along with higher depreciation and amortization, may have negatively affected the bottom line [4] Group 2: Q2 Expectations - The Zacks Consensus Estimate for earnings is $2.89 per share, reflecting a year-over-year increase of 1.4% [5] - The revenue estimate stands at $1.88 billion, indicating a year-over-year improvement of 14.4% [5] Group 3: Earnings Prediction - The company's Earnings ESP is +1.33%, suggesting a strong likelihood of an earnings beat [6] - Atmos Energy currently holds a Zacks Rank 2 (Buy), which supports the prediction of an earnings beat [7]